title: Paraoxonase 1 (PON1) attenuates diabetes development in mice through its antioxidative properties.
abstract: Paraoxonase 1 (PON1) is a lipo-lactonase which is associated with HDL and possesses antioxidative properties. Diabetes is characterized by increased oxidative stress and by decreased PON1 activity. We aimed to analyze whether oxidative status and PON1 levels in mouse sera and macrophages could affect streptozotocin (STZ)-induced diabetes development. We have used two models of mice under low oxidative stress: STZ-injected apolipoprotein E-deficient mice supplemented with the antioxidant vitamin E, and P47(phox) knockout mice. In both mice models the decreased serum basal oxidative stress, was associated with a decreased rate of diabetes development, compared with control STZ-injected apolipoprotein E-deficient mice or with C57BL mice respectively. These data suggest that oxidative stress accelerates diabetes development. Next, we analyzed the effect of PON1 on macrophage oxidative stress and on diabetes development in STZ-injected C57BL mice, PON1 knockout mice, and PON1 transgenic mice. PON1 overexpression was associated with decreased diabetes-induced macrophage oxidative stress, decreased diabetes development, and decreased mortality, in comparison to C57BL mice, and even more so when compared to PON1KO mice. We thus concluded that on increasing PON1 expression in mice, diabetes development is attenuated, a phenomenon which could be attributed to the antioxidative properties of PON1, as decrement of oxidative stress significantly attenuated STZ-induced diabetes development.
authors: The Lipid Research Laboratory, The Technion Faculty of Medicine, The Rappaport Family Institute for Research in the Medical Sciences and Rambam Medical Center, Haifa, Israel.
authors: Orit
authors: O
authors: Rozenberg
authors: Maayan
authors: M
authors: Shiner
authors: Michael
authors: M
authors: Aviram
authors: Tony
authors: T
authors: Hayek
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000378:metabolism*; D001057:Apolipoproteins E / Q000502:physiology; D043303:Aryldialkylphosphatase / Q000502:physiology*; D002478:Cells, Cultured; D003921:Diabetes Mellitus, Experimental / Q000201:enzymology / Q000473:pathology / Q000517:prevention & control*; D006801:Humans; D017737:Macrophages, Peritoneal / Q000166:cytology / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D008822:Mice, Transgenic; D019255:NADPH Oxidases / Q000502:physiology; D018384:Oxidative Stress; D017382:Reactive Oxygen Species / Q000378:metabolism*; D013311:Streptozocin
chemical_list: D000975:Antioxidants; D001057:Apolipoproteins E; D017382:Reactive Oxygen Species; D013311:Streptozocin; D019255:NADPH Oxidases; C060505:neutrophil cytosolic factor 1; D043303:Aryldialkylphosphatase